New HIV Drug Cenicriviroc Shows Non-Inferiority to Efavirenz and Activity Against Inflammation, Study Finds

Cenicriviroc (CVC), an investigational CCR5 antagonist, showed non-inferiority when compared to efavirenz (Sustiva, Stocrin) and strong anti-inflammatory indications, according to phase-2b study results presented at CROI 2013 in Atlanta.